Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focusing on Delivery of Bioactive Substances via Oral Ingestion

  • Lexaria has its patented DehydraTECH™ nutrient infusion technology
  • This technology has patent protection for cannabidiol and all other non-psychoactive cannabinoids
  • DehydraTECH™ technology provides greater bio-absorption

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a worldwide leader in enhancing the gastro-intestinal delivery of edible cannabinoid products. The company has its patented nutrient infusion technology called DehydraTECH™. This technology significantly improves the body’s ability to absorb cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, nicotine, drugs, supplements and other beneficial molecules. Lexaria Bioscience is headquartered in Kelowna, British Columbia.

Lexaria has patents granted in the United States and Australia for applications of its DehydraTECH™ technology. In addition, it has numerous patents pending in more than 40 countries. Issued and pending patents name a wide spectrum of lipophilic bioactives and food/carrier particles that can be formulated and delivered using the company’s DehydraTECH™ technology.

The company’s technology has patent protection for cannabidiol and all other non-psychoactive cannabinoids. In December 2017, the company received its first patent from the U.S. Patent Office, which covers nicotine, ibuprofen and aspirin delivery, along with cannabinoids.

In the cannabis business, Lexaria’s focus is to make infused foods taste more like food and less like marijuana, while providing many other benefits.  Fundamentally, the DehydraTECH™ technology makes it possible to transport bioactive substances by way of oral ingestion. DehydraTECH™ does so without the need for inhalational dosing. The technology also enhances the flavor and bouquet of cannabinoid edibles.

A major feature of DehydraTECH™ technology is that dosing doesn’t have to be combined with unhealthy sugars or sweeteners upon administering. Sugars and sweeteners are typically used to mask harsh tastes. The DehydraTECH™ delivery method removes the need for sugar-filled food. DehydraTECH™ features flavor-masking for poor tasting compounds.

The technology also reduces the time of onset of THC (tetrahydrocannabinol) effects. Moreover, it provides greater bio-absorption. Cannabinoids are usually poorly absorbed by the gastrointestinal system. However, Lexaria Biosciences’ DehydraTECH™ increases absorption by five to 10 times, which is equal to that of inhalation. Oral ingestion is also safer than inhalation with devices and involves fewer complexities.

The U.S. National Library of Medicine – National Institutes of Health notes in its article, ‘Inhalation Drug Delivery Devices: Technology Update’, that, “The major problems with the use of inhaler devices are the deposition of aerosolized particles in the oropharyngeal region and upper airways and the lack of coordination between the device activation and inhalation due to lack of patient training” (http://cnw.fm/TrK6u).

The company’s technology also provides protection during stomach transit. Furthermore, DehydraTECH™ bypasses first pass liver effect. The small intestine quickly absorbs LCFAs (Long-Chain Fatty Acids) into the lymphatic system and MCFAs (Medium-Chain Fatty Acids) through the liver.

Recently, Lexaria Bioscience announced lab test results regarding the delivery of nicotine via the gastrointestinal tract and first-rate nicotine absorption in animal blood plasma. The results show rapid speed of onset and bioavailability. These results have led to more and continuing dialogue with foremost nicotine industry participants concerning the possible use of the company’s technology for a smoke-free nicotine outlook. However, Lexaria is not partnering with the tobacco industry.

Lexaria’s DehydraTECH™ technology crosses the intestinal wall very effectively. The company is also studying if it affects blood-brain barrier transmission. If it does, Lexaria says that it has the potential to have major outcomes for biotechnology and pharmaceuticals along with cannabis.

For more information, visit the company’s website at www.LexariaEnergy.com

More from PsychedelicNewsWire

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050